24 results
8-K
ALLK
Allakos Inc
16 Jan 24
Allakos Announces a Restructuring to Focus on Development of AK006
5:00pm
, manufacturing, research and administrative functions. The Company also committed to reducing its workforce by approximately 50%.
The total costs … related to halting lirentelimab-related activities and reducing the workforce are estimated to be approximately $30 million, with the majority
8-K
EX-99.1
bgl6 qc5hxot
6 May 22
Allakos Provides Business Update and Reports First Quarter 2022 Financial Results
4:01pm
8-K
EX-99.1
94wzz9x5awsxb05h8h
16 Jan 24
Allakos Announces a Restructuring to Focus on Development of AK006
5:00pm
8-K
EX-99.1
qukmj r0c8dy1g9uplv
16 Jan 24
Regulation FD Disclosure
6:17pm
8-K
EX-99.1
46p0 kg5hljpfz
15 Feb 22
Other Events
8:00am
8-K/A
EX-99.1
b6ps1
15 Feb 22
Other Events
10:02am